ArticleOphthalmology science2026
Retinal Vascularity Index in Parkinson's Disease.
Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To assess differences in retinal vascularity index (RVI) between individuals with Parkinson's disease (PD) and controls to explore RVI as a potential retinal biomarker of PD. Design: Cross-sectional case-control study. Participants: One hundred sixty-eight eyes of 108 PD participants and 115 eyes of 71 control participants in the Eye Multimodal Imaging in Neurodegenerative Disease Study. Methods: Ultra-widefield (UWF) retinal color photographs were acquired in each participant using scanning laser ophthalmoscopy (California, Optos). Images were analyzed using a semiautomated software via the Comprehensive Ocular Imaging Network (ocularimaging.net). Retinal vascularity index was calculated as the ratio of arteriolar to venular cross-sectional area within a 47° region of interest (ROI) centered on the optic disc. Main Outcome Measures: Five RVI outcomes in the 47° ROI were compared between groups: total, superonasal, superotemporal, inferotemporal, and inferonasal (IN). Results: Mean total RVI was significantly higher in the PD group (0.790 ± 0.134) than in controls (0.696 ± 0.117, Conclusions: Retinal vascularity index was significantly higher in individuals with PD than in controls. These findings may reflect alterations in retinal vascular structure in PD. Discriminatory analyses suggest that RVI is currently unlikely to stand alone as a diagnostic tool. Further investigation is warranted to determine whether RVI derived from a 5-disc diameter area on UWF images may serve as a potential retinal biomarker of PD. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.